Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: An update on the evidence for efficacy and safety

Therapeutic Advances in Respiratory Disease

Volumn 9, Issue 2, 2015, Pages 49-55

  Ridolo, Erminia ^a   Montagni, Marcello ^a   Riario Sforza, Gian Galeazzo ^b   Baroni, Marco ^b   Incorvaia, Cristoforo ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b ICP Hospital   (Italy)

Author keywords

chronic obstructive pulmonary disease; glycopyrronium; indacaterol; muscarinic antagonists; treatment guidelines; 2 agonist

Indexed keywords

FLUTICASONE; GLYCOPYRRONIUM BROMIDE; INDACATEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DRUG COMBINATION; INDAN DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINOLONE DERIVATIVE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFICACY; DRUG SAFETY; ELEVATED BLOOD PRESSURE; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; LUNG FUNCTION; PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TACHYCARDIA; UPPER RESPIRATORY TRACT INFECTION; DRUG COMBINATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; DRUG COMBINATIONS; GLYCOPYRROLATE; HUMANS; INDANS; LUNG; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; TREATMENT OUTCOME;

EID: 84925856247     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465815572065     Document Type: Review

References (32)

1. Asai K. Minakata Y. Hirata K. (2013) QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: the ARISE study. Presented at the European Respiratory Society Congress 2013, Barcelona, poster number P3392.
2. Bateman E. Ferguson G. Barnes N. Gallagher N. Green Y. Henley M. (2013) Banerji D. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 42: 1484–1494.
3. Beeh K. Korn S. Beier J. Jadayel D. Henley M. D–Andrea P. (2014) Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med 108: 584–592.
4. Buhl R. Banerji D. (2012) Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis 7: 729–741.
5. Buhl R. Dunn L. Disdier C. Amos C. Henley M. Kramer B. (2011) Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 38: 797–803.
6. Cazzola M. Page C. Rogliani P. Matera M. (2013) Beta2-agonists therapy in lung disease. Am J Respir Crit Care Med 187: 690–696.
7. Chapman K. Rennard S. Dogra A. Owen R. Lassen C. Kramer B. (2011) Long-term safety and efficacy of indacaterol, a long-acting beta2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 140: 68–75.
8. Dahl R. Chapman K. Rudolf M. Mehta R. Kho P. Alagappan V. (2013a) Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med 107: 1558–1567.
9. Dahl R. Jadayel D. Alagappan V. Chen H. Banerji D. (2013b) Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis 8: 501–508.
10. Donohue J. Fogarty C. Lötvall J. Mahler D. Worth H. Yorgancioglu A. (2010) Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 182: 155–162.
11. D–Urzo A. Ferguson G. van Noord J. Hirata K. Martin C. Horton R. (2011) Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 12: 156.
12. Feldman G. Siler T. Prasad N. Jack D. Piggott S. Owen R. (2010) Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 10: 11–20.
13. Keating G. (2012) Tiotropium bromide inhalation power: a review of its use in the management of chronic obstructive pulmonary disease. Drugs 72: 273–300.
14. Kerwin E. Hébert J. Gallagher N. Martin C. Overend T. Alagappan V. (2012) Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 40: 1106–1114.
15. Korn S. Kerwin E. Atis S. Amos C. Owen R. Lassen C. (2011) Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med 105: 719–726.
16. Kornmann O. Dahl R. Centanni S. Dogra A. Owen R. Lassen C. (2011) Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 37: 273–279.
17. Laforce C. Aumann J. Parreno L. Iqbal A. Young D. Owen R. (2011) Sustained 24-hour efficacy of once-daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, cross-over study. Pulm Pharmacol Ther 24: 162–168.
18. Mahler D. Decramer M. D–Urzo A. Worth H. White T. Alagappan V. (2014) Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J 43: 1599–1609.
19. Mahler D. D–Urzo A. Bateman E. Ozkan S. White T. Peckitt C. (2012) Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 67: 781–788.
20. O–Donnell D. Casaburi R. Vincken W. Puente-Maestu L. Swales J. Lawrence D. (2011) Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 105: 1030–1036.
21. Ridolo E. Montagni M. Olivieri E. Riario-Sforza G. Incorvaia C. (2013) Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review. Int J Chron Obstruct Pulmon Dis 8: 425–432.
22. Van de Maele B. Fabbri L. Martin C. Horton R. Dolker M. Overend T. (2010) Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients. COPD 7: 418–427.
23. Van Noord J. Aumann J. Janssens E. Smeets J. Zaagsma J. Mueller A. (2010a) Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir Med 104: 995–1004.
24. Van Noord J. Buhl R. Laforce C. Martin C. Jones F. Dolker M. (2010b) QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 65: 1086–1091.
25. Vestbo J. Hurd S. Agustí A. Johns P. Vogelmeier C. Anzueto A. (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187: 347–365.
26. Vogelmeier C. Bateman E. Pallante J. Alagappan V. D–Andrea P. Chen H. (2013) Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 1: 51–60.
27. Vogelmeier C. Kardos P. Harari S. Gans S. Stenglein S. Thirlwell J. (2008) Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 102: 1511–1520.
28. Vogelmeier C. Ramos-Barbon D. Jack D. Piggott S. Owen R. Higgins M. (2010a) Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res 11: 135–139.
29. Vogelmeier C. Verkindre C. Cheung D. Galdiz J. Güçlü S. Spangenthal S. (2010b) Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther 23: 438–444.
30. Vincken W. Aumann J. Chen H. Henley M. McBryan D. Goyal P. (2014) Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis 9: 215–228.
31. Wedzicha J. Dahl R. Buhl R. Schubert-Tennigkeit A. Chen H. D–Andrea P. (2014) Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med 108: 1498–1507.
32. Wedzicha J. Decramer M. Ficker J. Niewoehner D. Sandström T. Taylor A. (2013) Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 1: 199–209.